Phase 4 N=120 Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes
Type 1 Diabetes
Primary: Change of 3-hour Mean Area Under the Curve (AUC) of C-peptide — -0.01; -0.35 pmol/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=19 Exogenous Ketones in Type 2 Diabetes
Ketosis · Type 2 Diabetes
Primary: Plasma Glucose — 7.3; 7.2; 6.2; 6.6 mmol/L
N/A N=104 Start Treatment and Recovery for Opioid Use Disorder
Opioid-use Disorder · Mental Disorder · Opioid Medication Assisted Treatment
Primary: Number of Participants With Self-reported Treatment Retention — 51 Participants
Phase 2 N=38 Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease
Metastatic Breast Cancer · Liver Metastases
Primary: Response Rate — 2; 13; 21; 1 Participants
Phase 3 N=123 Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
Immune Thrombocytopenic Purpura
Primary: Percentage of Subjects Who Achieved Platelet Count of at Least 50,000/µL Within 12 Weeks of Beginning Treatment up to 12 Months (Fostamatinib in 047/048 or 049):Version…
N/A N=402 Satisfactory Analgesia Minimal Emesis in Day Surgeries
Pain · Post Operative Nausea and Vomiting
Primary: Our Combined Primary Outcome Will be Number of Patients With Same Analgesia Minimal Emesis, as Compared Between the 2 Groups. — 172; 175 Participants — p=0.997
Phase 1 N=43 A Phase I, Open-Label, Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Participants
Healthy Volunteers
Primary: Maximum Observed Plasma Concentration (Cmax) — 238.6; 341.3; 3831; 4891 pg/mL
Phase 3 N=49 An Extension Study of WA19926 of the Long-Term Safety of Tocilizumab (RoActemra/Actemra) in Patients With Early Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs of Special Interest (AESIs) — 69.4; 10.2; 17.2 percentage of participants
Phase 1 N=32 A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers
Healthy Volunteers
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 2; 1; 0; 1 Participants
N/A N=205 A Post-market Clinical Evaluation of St. Jude Medical™ MR Conditional ICD System on Patients Undergoing Magnetic Resonance Imaging
ICD · Tachycardia
Primary: Number of Participants With Freedom From MRI-scan Related Complications* Related to St. Jude Medical™ MR Conditional ICD System — 177 Participants
Phase 3 N=35 Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)
HIV-1 Infection
Primary: Percentage of Participants Receiving Doravirine/Islatravir (DOR/ISL) With ≥0.5 log10 Change From Day 1 Baseline to Day 8 in Human Immunodeficiency Virus Type 1 (HIV-1)…
N/A N=3,061 Control-IQ Observational (CLIO) Post-Approval Study
Diabetes Mellitus, Type 1
Primary: Incidence Rates of Severe Hypoglycemia (SH) — 9.65; 9.31; 9.77; 7.99 events per 100 patient years
N/A N=106 Postpartum Pre-exposure Prophylaxis (PrEP) Study to Evaluate an Adherence Promotion Package for Postpartum Women on PrEP
HIV-1-infection
Primary: Recent PrEP Adherence — 33; 18 Participants — p=<0.001
N/A N=180 Evaluation of Secondary Distribution of HIV Self-screening Tests by Women With HIV
HIV Infections · ART · HIV Seropositivity
Primary: Partner HIV Testing — 66; 50 Participants — p=<0.05
Phase 3 N=605 Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®
Asthma
Primary: Change From Baseline in Weekly Average of Daily Trough (Predose and Pre-rescue Bronchodilator) Morning (AM) Peak Expiratory Flow (PEF) Over the 12-Week Treatment Period…